During the first 2 weeks of treatment, mice treated with anti-αvβ3 CAR-T cells with a CD28 co-stimulatory domain showed rapid tumor regression, while in mice treated with CAR-T cells with a 4-1BB co-stimulatory domain, tumor volume decreased, but it was still detectable. The gene discussed is CD28; the disease is neoplasm.